Turn Therapeutics (TTRX) Operating Leases (2024 - 2026)

Turn Therapeutics (TTRX) posted quarterly Operating Leases of $21539.0 for Q1 2026, down 36.8% quarter-over-quarter from $34081.0 in Q4 2025.

Turn Therapeutics (TTRX) Operating Leases (2024 - 2026) Analysis & Trends

Turn Therapeutics' Operating Leases history runs 3 years deep, the most recent figure standing at $21539.0 for Q1 2026.

In Q1 2026, Operating Leases changed N/A year-over-year to $21539.0; the TTM figure through Mar 2026 stood at $21539.0 (changed N/A YoY), while the FY2025 annual figure was $34081.0, down 57.6% from the prior year.
Operating Leases for Q1 2026 stood at $21539.0, down from $34081.0 in the prior quarter.
The five-year high for Operating Leases was $80376.0 in Q4 2024, with the low at $21539.0 in Q1 2026.
The 3-year median for Operating Leases is $40212.5 (2025), against an average of $45585.0.
Peak annual rise in Operating Leases reached 57.6% in 2025, while the deepest fall reached 57.6% in 2025.
Turn Therapeutics' Operating Leases stood at $80376.0 in 2024, then slumped by 57.6% to $34081.0 in 2025, then sank by 36.8% to $21539.0 in 2026.
Business Quant data shows TTRX's Operating Leases at $21539.0 in Q1 2026, $34081.0 in Q4 2025, and $46344.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Turn Therapeutics	285.07 Mn	285.07 Mn	-

Download Data